期刊
ONCOTARGET
卷 7, 期 29, 页码 44876-44878出版社
IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.10381
关键词
mTOR; target of rapamycin; healthspan; mitochondria; mitochondria disease
资金
- NIH [F32AG050444]
- Glenn Foundation
- University of Washington Nathan Shock Center of Excellence in the Basic Biology of Aging [P30AG013280]
- Alzheimer's Disease Research Center [P50AG005136]
Experimental geroscience has identified rapamycin as a top candidate for promoting healthy aging and longevity in mammals. As multiple independent studies have successfully reproduced the lifespan and healthspan promoting effects of rapamycin, the focus has shifted to possible translational use. While a promising compound, clinical use of rapamycin is limited by concerns of side effects associated with the drug. Studies aimed at defining optimal dosage regimen, delivery route, and formulation will allow for benefits to be maximized while reducing side effects.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据